Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,029 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Positron Emission Tomography Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand

NCT02056249
View directory record Official record
Conditions
Hypoglycemia
Interventions
Norepinephrine Transporter (NET) ligand
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB

NCT00527579
View directory record Official record
Conditions
Neurocysticercosis, Healthy
Interventions
[F-18]FBR
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 9, 2026, 2:53 PM EDT
Recruiting Phase 2 Interventional

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

NCT07673341
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241
View directory record Official record
Conditions
Depression
Interventions
ABP688
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 9, 2026, 2:53 PM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 9, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 9, 2026, 2:53 PM EDT
Withdrawn Phase 2 Interventional

Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

NCT04298541
View directory record Official record
Conditions
Meningioma
Interventions
Ga-68- DOTATATE, Ga-68-DOTATOC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Study of Temsirolimus, Topotecan, and Bortezomib

NCT00770731
View directory record Official record
Conditions
Advanced Cancer
Interventions
Torisel (Temsirolimus), Hycamtin (Topotecan), Velcade (Bortezomib)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 9, 2026, 2:53 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

NCT01000870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-513-01
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

NCT04057807
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LPS
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

NCT01774071
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr DFO-MSTP2109A
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 9, 2026, 2:53 PM EDT
Not yet recruiting Early Phase 1 Interventional

[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

NCT07026981
View directory record Official record
Conditions
Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
Interventions
[Ga-68]MTP220 PET/CT Scan
Drug
Lead sponsor
Qiubai Li
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 9, 2026, 2:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Acapatamab, Enzalutamide, Abiraterone, AMG 404
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 9, 2026, 2:53 PM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

NCT02414230
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 2 Interventional Results available

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

NCT00559377
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography, tissue oxygen measurement
Other · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

NCT01253655
View directory record Official record
Conditions
Healthy
Interventions
PF-05212365
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 9, 2026, 2:53 PM EDT
Completed No phase listed Observational

Positron Emission Tomography in Patients With Breast Cancer

NCT00001385
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 2:53 PM EDT
Withdrawn Phase 2 Interventional

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

NCT02707978
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 9, 2026, 2:53 PM EDT
Recruiting Phase 2 Interventional

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

NCT04205604
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
18F-Fluoro Dopa Imaging
Drug
Lead sponsor
Miguel Pampaloni
Other
Eligibility
0 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 9, 2026, 2:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography (PET), Trastuzumab, Pertuzumab
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Early Phase 1 Interventional

PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A

NCT01198197
View directory record Official record
Conditions
Pain, Anxiety, Depression
Interventions
NOP-1A
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 9, 2026, 2:53 PM EDT
Completed Phase 1 Interventional

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT01017133
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography
Radiation · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 9, 2026, 2:53 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 9, 2026, 2:53 PM EDT